Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | HTR2B | P41595 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15472314 | 0.86 | HTT (0.47) | NPC1RAB9ASMN1; SMN2ALOX5POLB | |
| SCHEMBL15132936 | 0.85 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2POLBRXFP1 | |
| SCHEMBL3997492 | 0.84 | RAB9A (0.63) | NPC1RAB9ASMN1; SMN2ALOX5MAPT | |
| SCHEMBL28745911 | 0.84 | ALOX5 (0.49) | NPC1RAB9ASMN1; SMN2ALOX5MAPT | |
| SCHEMBL7861771 | 0.84 | SMN1; SMN2 (0.71) | NPC1RAB9ASMN1; SMN2ALOX5POLB | |
| SCHEMBL12090778 | 0.81 | MAPT (0.66) | NPC1RAB9ASMN1; SMN2MAPTHTT | |
| SCHEMBL13117927 | 0.79 | SMN1; SMN2 (0.52) | NPC1RAB9ASMN1; SMN2ALOX5POLB | |
| SCHEMBL14530529 | 0.79 | GAA (0.53) | NPC1RAB9ASMN1; SMN2ALOX5MAPT | |
| SCHEMBL9502821 | 0.79 | MAPT (0.63) | NPC1RAB9ASMN1; SMN2ALOX5MAPT | |
| SCHEMBL3098479 | 0.78 | NPC1 (0.51) | NPC1RAB9ASMN1; SMN2ALOX5MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187437-B2 | Substituted oxadiazole compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-17 | — | — | US | disclosed |
| US-20130190361-A1 | SUBSTITUTED OXADIAZOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-25 | — | — | US | disclosed |
| US-7741345-B2 | AZA-peptide protease inhibitors | GILEAD SCIENCES, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741345-B2 | AZA-peptide protease inhibitors | GILEAD SCIENCES, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7723380-B2 | Tetrahydrofuro[2,3-b]furyl carbamates containing an (oxy)hydrazide group; these compounds target the HIV protease in both wild type and mutant strains of HIV. | GILEAD SCIENCES, INC. (US) | 2010-05-25 | — | — | US | disclosed |
| US-20090306112-A1 | ANTIVIRAL PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090105279-A1 | Antiviral protease inhibitors | GILEAD SCIENCES, INC. | 2009-04-23 | — | — | US | disclosed |
| US-20090099096-A1 | AZA-peptide protease inhibitors | GILEAD SCIENCES, INC. | 2009-04-16 | — | — | US | disclosed |
| US-20090099096-A1 | AZA-peptide protease inhibitors | GILEAD SCIENCES, INC. | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105279-A1 | Antiviral protease inhibitors | ACE, TMPRSS15, MME | NPC1 406/4885RAB9A 1820/4885SMN1; SMN2 2343/4885 |
| US-20130190361-A1 | SUBSTITUTED OXADIAZOLE COMPOUNDS | S1PR1, S1PR3, S1PR2 | NPC1 837/4885RAB9A 1971/4885SMN1; SMN2 1458/4885 |
| US-20090099096-A1 | AZA-peptide protease inhibitors | DNPEP, ANPEP, PEPD | NPC1 1414/4885RAB9A 1497/4885SMN1; SMN2 2815/4885 |
| US-20090306112-A1 | ANTIVIRAL PROTEASE INHIBITORS | ACE, DNPEP, TMPRSS15 | NPC1 375/4885RAB9A 1786/4885SMN1; SMN2 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.